• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide.

作者信息

Breithaupt B, Tittel M

出版信息

Eur J Clin Pharmacol. 1982;22(1):77-84. doi: 10.1007/BF00606429.

DOI:10.1007/BF00606429
PMID:7094977
Abstract

An high-pressure liquid chromatographic method was used to measure allopurinol and oxipurinol in plasma and urine in 6 healthy volunteers after a single intravenous or oral dose of allopurinol. The influence of coadministered benzbromarone and hydrochlorothiazide on the pharmacokinetics of allopurinol and oxipurinol was also investigated. After intravenous injection of allopurinol 300 mg the plasma disappearance was biexponential, with a mean distribution half-life of 2.32 +/- 1.08 min (mean +/- SD) and an elimination half-life of 47.8 +/- 10.6 min. The total clearance of allopurinol was 11.37 +/- 2.70 ml/min/kg, whereas its renal clearance was only 1.73 +/- 0.79 ml/min/kg. Oxipurinol disappeared monoexponentially from plasma with a mean half-life of 12.2 +/- 2.6 h. Its renal clearance was 0.42 +/- 0.091 ml/min/kg. After oral administration of allopurinol 300 mg the peak plasma concentration of 2.1 +/- 0.6 micrograms/ml (1.5 x 10(-5) M) was reached within 30 to 120 min. The peak level of oxipurinol of 5.8 +/- 1.5 micrograms/ml (3.8 x 10(-5) M) was found within 2 to 5 h after intravenous and oral allopurinol. The bioavailability of oral allopurinol computed from plasma data was 90.4 +/- 8.7%. The total recovery from urine was 77% (allopurinol 8%, oxipurinol 69%) after oral and 88% after i.v. administration. It was concluded that about 10% of the oral dose was not absorbed and that 12% was eliminated by an unknown mechanism, presumably as riboside. The pharmacokinetics of allopurinol and oxipurinol were not significantly influenced by coadministration of benzbromarone or hydrochlorothiazide.

摘要

相似文献

1
Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide.
Eur J Clin Pharmacol. 1982;22(1):77-84. doi: 10.1007/BF00606429.
2
Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone.长期口服给药后别嘌醇和氧嘌呤醇的动力学。与苯溴马隆的相互作用。
Eur J Clin Pharmacol. 1986;31(1):53-8. doi: 10.1007/BF00870986.
3
[Influence of benzbromarone on the pharmacokinetics and pharmacodynamics of oxipurinol].
Arzneimittelforschung. 1982;32(9):1149-52.
4
Allopurinol kinetics and bioavailability. Intravenous, oral and rectal administration.
Cancer Chemother Pharmacol. 1982;8(1):93-8. doi: 10.1007/BF00292878.
5
Allopurinol kinetics.
Clin Pharmacol Ther. 1978 May;23(5):598-605. doi: 10.1002/cpt1978235598.
6
Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects. II. Kinetics of allopurinol, oxipurinol, and hydrochlorothiazide.在正常受试者中长期口服别嘌醇和氢氯噻嗪期间两者的相互作用。II. 别嘌醇、氧嘌呤醇和氢氯噻嗪的动力学
Clin Investig. 1994 Dec;72(12):1076-81. doi: 10.1007/BF00577759.
7
Evaluation of a thiazide-allopurinol drug interaction.
Am J Med Sci. 1986 Oct;292(4):213-6. doi: 10.1097/00000441-198610000-00006.
8
[Time course of oxipurinol levels in plasma following single dose and chronic administration of allopurinol in different pharmaceutical preparations (author's transl)].
Arzneimittelforschung. 1979;29(5):839-42.
9
[Excretion and serum concentrations of allopurinol, oxipurinol and oxipurines in combined treatment with allopurinol and benzbromarone in increasing doses].[在递增剂量的别嘌醇与苯溴马隆联合治疗中别嘌醇、氧嘌呤醇和氧嘌呤类的排泄及血清浓度]
Med Welt. 1983 Sep 9;34(36):974-9.
10
Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects. I. Uric acid kinetics.在正常受试者中长期口服别嘌醇和氢氯噻嗪期间二者的相互作用。I. 尿酸动力学
Clin Investig. 1994 Dec;72(12):1071-5. doi: 10.1007/BF00577758.

引用本文的文献

1
Characterisation and evaluation of predisposing factors for the development of xanthinuria in dogs with leishmaniosis under allopurinol therapy.在别嘌呤醇治疗下,对患有利什曼病的犬类黄嘌呤尿症发生的诱发因素进行特征描述和评估。
Parasit Vectors. 2025 Mar 10;18(1):98. doi: 10.1186/s13071-025-06731-0.
2
Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates.缺氧缺血性脑病新生儿别嘌醇、其活性代谢物氧嘌呤醇以及生物标志物次黄嘌呤、黄嘌呤和尿酸的药代动力学/药效学建模。
Clin Pharmacokinet. 2022 Feb;61(2):321-333. doi: 10.1007/s40262-021-01068-0. Epub 2021 Oct 7.
3

本文引用的文献

1
THE EFFECTIVENESS OF THE XANTHINE OXIDASE INHIBITOR ALLOPURINOL IN THE TREATMENT OF GOUT.黄嘌呤氧化酶抑制剂别嘌醇治疗痛风的疗效
Ann Intern Med. 1965 Apr;62:639-47. doi: 10.7326/0003-4819-62-4-639.
2
EFFECT OF ALLOPURINOL (4-HYDROXYPYRAZOLO-(3,4-D)PYRIMIDINE) ON SERUM AND URINARY URIC ACID IN PRIMARY AND SECONDARY GOUT.别嘌醇(4-羟基吡唑并[3,4-d]嘧啶)对原发性和继发性痛风患者血清及尿尿酸的影响
Am J Med. 1964 Dec;37:885-98. doi: 10.1016/0002-9343(64)90131-7.
3
THE ENZYMOLOGY OF FEEDBACK INHIBITION OF GLUTAMINE PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE BY PURINE RIBONUCLEOTIDES.
A Brief Review of Analytical Methods for the Estimation of Allopurinol in Pharmaceutical Formulation and Biological Matrices.
药物制剂和生物基质中别嘌醇含量测定分析方法的简要综述
Int J Anal Chem. 2021 Jun 5;2021:5558651. doi: 10.1155/2021/5558651. eCollection 2021.
4
Reply to "Restricting maintenance allopurinol dose according to kidney function in patients with gout is inappropriate!" by Stamp et al.对斯坦普等人《痛风患者根据肾功能限制别嘌醇维持剂量是不合适的!》一文的回复
Br J Clin Pharmacol. 2019 Jun;85(6):1380-1381. doi: 10.1111/bcp.13924. Epub 2019 Apr 13.
5
Simultaneous analysis of allopurinol and oxypurinol using a validated liquid chromatography-tandem mass spectrometry method in human plasma.采用经过验证的液相色谱-串联质谱法同时分析人血浆中的别嘌醇和氧嘌呤醇。
J Pharm Anal. 2017 Feb;7(1):56-62. doi: 10.1016/j.jpha.2016.05.005. Epub 2016 May 26.
6
Protection against acetaminophen-induced liver injury by allopurinol is dependent on aldehyde oxidase-mediated liver preconditioning.别嘌醇通过醛氧化酶介导的肝脏预处理来防止对乙酰氨基酚引起的肝损伤。
Toxicol Appl Pharmacol. 2014 Feb 1;274(3):417-24. doi: 10.1016/j.taap.2013.12.003. Epub 2013 Dec 15.
7
The population pharmacokinetics of allopurinol and oxypurinol in patients with gout.别嘌醇和氧嘌呤醇在痛风患者中的群体药代动力学。
Eur J Clin Pharmacol. 2013 Jul;69(7):1411-21. doi: 10.1007/s00228-013-1478-8. Epub 2013 Mar 10.
8
Allopurinol reduces antigen-specific and polyclonal activation of human T cells.别嘌醇可降低人 T 细胞的抗原特异性和多克隆活化。
Front Immunol. 2012 Sep 21;3:295. doi: 10.3389/fimmu.2012.00295. eCollection 2012.
9
Lack of effect of hydrochlorothiazide and low-dose aspirin on the renal clearance of urate and oxypurinol after a single dose of allopurinol in normal volunteers.正常志愿者单次别嘌醇给药后,氢氯噻嗪和小剂量阿司匹林对尿酸和氧嘌呤醇肾清除率无影响。
Eur J Clin Pharmacol. 2011 Jul;67(7):709-13. doi: 10.1007/s00228-010-0963-6. Epub 2010 Dec 23.
10
Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.别嘌醇和氧嘌呤醇的临床药代动力学与药效学
Clin Pharmacokinet. 2007;46(8):623-44. doi: 10.2165/00003088-200746080-00001.
嘌呤核糖核苷酸对谷氨酰胺磷酸核糖焦磷酸酰胺转移酶反馈抑制的酶学研究
J Biol Chem. 1964 Aug;239:2570-9.
4
4-HYDROXYPYRAZOLO (3,4-D) PYRIMIDINE (HPP) IN THE TREATMENT OF GOUT: PRELIMINARY OBSERVATIONS.4-羟基吡唑并(3,4 -d)嘧啶(HPP)治疗痛风:初步观察
Ann Rheum Dis. 1964 Nov;23(6):439-46. doi: 10.1136/ard.23.6.439.
5
Determination of allopurinol and oxipurinol in biological fluids by high-performance liquid chromatography.用高效液相色谱法测定生物流体中的别嘌醇和氧嘌呤醇。
J Chromatogr. 1981 Nov 13;226(1):237-42. doi: 10.1016/s0378-4347(00)84228-0.
6
Ribonucleosides of allopurinol and oxoallopurinol. Isolation from human urine, enzymatic synthesis, and characterization.别嘌醇和氧代别嘌醇的核糖核苷。从人尿中分离、酶促合成及表征。
J Biol Chem. 1967 Jun 10;242(11):2675-82.
7
Metabolic studies of allopurinol, an inhibitor of xanthine oxidase.黄嘌呤氧化酶抑制剂别嘌醇的代谢研究。
Biochem Pharmacol. 1966 Jul;15(7):863-80. doi: 10.1016/0006-2952(66)90163-8.
8
Urinary excretion of purines, pyrimidines and pyrazolopyrimidines in patients treated with allopurinol or oxipurinol.接受别嘌醇或氧嘌呤醇治疗的患者嘌呤、嘧啶及吡唑并嘧啶的尿排泄情况。
Clin Chim Acta. 1969 Feb;23(2):353-64. doi: 10.1016/0009-8981(69)90052-7.
9
Renal clearance of oxipurinol, the chief metabolite of allopurinol.
Am J Med. 1968 Jul;45(1):69-77. doi: 10.1016/0002-9343(68)90008-9.
10
An enzymatic basis for variation in response to allopurinol. Hypoxanthine-guanine phosphoribosyltransferase deficiency.别嘌醇反应差异的酶学基础。次黄嘌呤-鸟嘌呤磷酸核糖转移酶缺乏症。
N Engl J Med. 1968 Feb 8;278(6):287-93. doi: 10.1056/NEJM196802082780601.